# **DSM** CAPITAL 31 March 2024 **PARTNERS** DSM Global Growth Equity Fund

#### INVESTMENT MANAGER

- Established 2001
- \$7.5 B AUM
- 100% employee and founder owned
- Headquartered in Palm Beach Gardens, FL

### INVESTMENT OBJECTIVE

- Long-term focus on predictable growth
- Valuation discipline seeks to reduce high P/E risk
- Concentrated 25 50 stock portfolio

### DISTINGUISHING FEATURES

- Valuation Discipline: Designed to avoid purchase of overvalued stocks. Provides price targets to create sales of appreciated securities.
- **Research:** Consistently applied fundamental research and detailed proprietary earnings models help distinguish between what is important and substantive versus simply noise. The combination of research and valuation discipline aims to reduce risk and enhance return.
- **Culture:** Team-oriented portfolio management process encourages objectivity. Analyst/ PMs incentivized to have the best companies in the portfolio regardless of coverage.
- Alignment of Interests: The team has significant personal investment in DSM portfolios creating a critical alignment with client's interests.

# **INVESTMENT TEAM MEMBERS**

	Experience		
Managing Partner	DSM	Industry	
Daniel Strickberger Chief Investment Officer	23	43	
Portfolio Managers/Analysts			
David McVey, CFA Deputy Chief Investment Officer	22	28	
Eric Woodworth, CFA Deputy Chief Investment Officer	22	23	
Shirley Hu Anderson, CFA	2	17	
Justin Burk, CFA	21	26	
Hannah Chiang	8	26	
Giles Evans, CFA	2	5	
Takamune Fujikawa, CFA	5	29	
Steve Tish, CFA	16	32	

Enquiries: Clearway Capital Solutions t: +61 2 9231 4350 m. +61 0 409 312 096 w. www.clearwaycapital.com.au e. dsmcapital@clearwaycapital.com.au

# AVERAGE ANNUAL RETURNS AS OF 31/03/2024 (AUD %)

	YTD	MRQ	l Yr	3 Yr	5 Yr	l0 Yr	SI*
DSM Global Growth Equity Fund	16.54%	16.54%	32.73%	6.16%	%	%	4.46%
MSCI ACWI Net Total Return	13.16%	13.16%	26.49%	12.62%	%	%	12.44%
DSM Global Growth Strategy Net*	18.27%	18.27%	37.64%	7.93%	12.82%	15.04%	15.30%
MSCI ACWI Net Total Return	13.16%	13.16%	26.49%	12.62%	12.82%	12.54%	12.57%

\*Model Fee / Fund Inception Date: 09-Feb-2021 / Strategy Inception Date: 01-Oct-2010

Performance data quoted represents past performance; past performance does not guarantee future results. The results are preliminary and unaudited. This presentation is supplemental information to the fully compliant composite performance disclosure available at <u>www.dsmcapital.com</u>.

# FUND CHARACTERISTICS<sup>1</sup>

	Portfolio	MSCI All Country World Index Net
Number of Holdings	31	2,841
Weighted Averge Market Capitalization (\$b)	1,447.9	803.2
P/E (Weighted Average, Trailing 12 Months)	41.4	20.8
P/E (Weighted Average, Forward 12 Months)	25.2	16.4
Price to Book Ratio (Trailing 12 Months)	7.5	3.0
Long-term Debt to Capital (%)	27.2	36.2
Dividend Yield (%)	0.4	1.9
Active Share (%)	83	

<sup>1</sup>Source FactSet

# RATINGS



The rating issued 05/2023 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2023 Lonsec. All rights reserved.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system is of needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.

# DSM CAPITAL 31 March 2024 PARTNERS DSM Global Growth Equity Fund

#### SECTOR ALLOCATION

	Fund	Rela	ative to MSCI ACWI	
Communication Services	9.2		1.6	
Consumer Discretionary	10.5	-0.4		
Consumer Staples		-6.4		
Energy		-4.5		
Financials	10.5	-5.6		
Health Care	4.4	-6.8		
Industrials	2.9	-7.9		
Information Technology	61.7			38.0
Materials		-4.2		
Real Estate		-2.2		
Utilities		-2.5		
[Cash]	1.0	- -	1.0	

# FUND FACTS

Responsible Entity	Equity Trustees Limited
Portfolio Manager	DSM Capital Partners
Investment Manager	Mantis Funds
Sales/Marketing Manager	Clearway Capital Solutions
Fund Inception date	9 February 2021
Strategy Inception date	l October 2010
APIR	ETL0199AU
Base currency	Australian Dollars
Management fee	0.99% of NAV
Performance fee	None
Investment minimums	AUD 25,000
Buy/sell spread	0.1%
Liquidity	Daily
Benchmark	MSCI All Country World Index Net
Platforms	BT, Macquarie, Hub24, Netwealth, Powerwrap

REGIONAL ALLOCATION				
	Fund	Relative to MSCI ACWI		
Developed	93.5	1.3		
Americas	76.3	9.5		
Europe	13.7	-1.6		
Middle East	3.5	3.4		
Pacific		-10.0		
Emerging	5.6	-2.2		
Africa		-0.3		
Americas		-0.9		
Asia	3.3	1.5		
Europe		-0.3		
Middle East		-0.7		
Pacific	2.3	-1.7		
[Cash]	1.0	1.0		

## TOP 10 HOLDINGS

NVIDIA Corporation	11.0
Microsoft Corporation	8.9
Amazon.com, Inc.	6.6
Arista Networks, Inc.	5.5
Alphabet Inc. Class A	5.4
ASML Holding NV	4.9
Intuit Inc.	4.7
Visa Inc. Class A	4.0
NICE Ltd.	3.3
Evolution AB	3.2

%

The Top 10 Holdings are as of the prior month end.

DISCLAIMER: Equity Trustees Limited ('EQT') (ABN 46 004 031 298 AFSL 240975) is the Responsible Entity for the DSM Global Growth Equity Fund. The material contained in this communication (and all its attachments) is general information only and has been prepared by DSM Capital Partners LLC ("DSM"). DSM is exempt from the requirement to hold an Australian Financial Services Licence under the Corporations Act in respect of the financial services it provides to wholesale clients only in Australia. It is not intended to take the place of professional advice and you should not act on any information made in this communication without first consulting your investment advisor in order to ascertain whether the information is appropriate, having regard to your investment objectives, financial situation and particular needs. Nothing in this communication shall be construed as a solicitation to buy or sell a security or to engage in or refrain from engaging in any transaction. DSM believe that the information contained herein is correct at the time of compilation. However, DSM and EQT provide no representation or warranty that it is accurate, complete, reliable or up to date, nor does DSM or EQT accept any obligation to correct or update the opinions (if any) in it. The opinions (if any) expressed are subject to change without notice. DSM and EQT do not accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of the material contained in this communication. This communication may refer to the past performance of a person, entity or financial product. Past performance is not a reliable indicator of future performance. Investors should obtain the relevant product disclosure statement and consider it before making any decision to invest.

DSM Global Growth Equity Fund's Target Market Determination is available on the <u>EQT website</u>. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.